Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer

1 Oct 2007

Abstract excerpt

First line therapy for non-small cell lung carcinoma (NSCLC) commonly includes combination therapy with a tubulin-binding agent (TBA) and a DNA-damaging agent. TBAs suppress microtubule dynamics by binding to the beta-tubulin subunit of alpha/beta-tubulin, inducing mitotic arrest and apoptosis. Up-regulation of class III beta-tubulin (betaIII-tubulin) has been implicated in clinical resistance in NSCLC, ovarian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Treatments and Mutations
Share to Synthesis and biological activity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17909044
DOI: 10.1158/0008-5472.can-07-0509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung CancerPMID 17909044Read ↗

Specific β-Tubulin Isotypes Can Functionally Enhance or Diminish Epothilone B Sensitivity in Non-Small Cell Lung Cancer CellsSemantic proximity Read ↗

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.Semantic proximity Read ↗

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.Semantic proximity Read ↗

Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to TaxolSemantic proximity Read ↗

<i>TUBB3</i> /βIII-Tubulin Acts through the PTEN/AKT Signaling Axis to Promote Tumorigenesis and Anoikis Resistance in Non–Small Cell Lung CancerSemantic proximity Read ↗

Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III β‐tubulinSemantic proximity Read ↗

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceSemantic proximity Read ↗

Mutational analysis of the class I β‐tubulin gene in human breast cancerSemantic proximity Read ↗

Class III β-tubulin expression and in vitro resistance to microtubule targeting agentsSemantic proximity Read ↗

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Semantic proximity Read ↗

Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized TrialSemantic proximity Read ↗

Analysis of beta-tubulin gene alteration in human lung cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.